(Reuters) - U.S. health regulators on Wednesday approved Sanofi's diabetes drug Toujeo, a more potent follow-up to the French drugmaker's top-selling insulin product Lantus.
The Food and Drug Administration approved the once daily, long-acting basal insulin to treat adults with both type 1 and the far more prevalent type 2 diabetes.
20:46 Arizona Cardinals pick up fifth-year option on LB Deone Bucannon for 2018 season16
15:02 Instagram Just Keeps Growing Like Crazy26
09:22 French Open organizers boost prize money by 12 percent10
01:48 Trump to propose large increase in deductions Americans can claim on their taxes18